CD4 and serum lipopolysaccharide activity: Intravenous immunoglobulin (IVIg) treatment significantly reduces endotoxemia and PD-1+ expression on CD4+ T cells, restoring bacteria-specific CD4+ T cell cytokine production and proliferation [11] and reducing CD8+ T cell activation [12].